Detalhe da pesquisa
1.
Human-centered participatory co-design with children and adults for a prototype lifestyle intervention and implementation strategy in a rural middle school.
BMC Public Health
; 24(1): 845, 2024 Mar 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-38504193
2.
Omecamtiv mecarbil does not prolong QTc intervals at therapeutic concentrations.
Br J Clin Pharmacol
; 88(1): 187-198, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34131942
3.
Population Pharmacokinetic Properties of Omecamtiv Mecarbil in Healthy Subjects and Patients With Heart Failure With Reduced Ejection Fraction.
J Cardiovasc Pharmacol
; 79(4): 539-548, 2022 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34983909
4.
Estimation of time to progression and post progression survival using joint modeling of summary level OS and PFS data with an ordinary differential equation model.
J Pharmacokinet Pharmacodyn
; 49(4): 455-469, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35870059
5.
Pharmacokinetics, Disposition, and Biotransformation of [14C]Omecamtiv Mecarbil in Healthy Male Subjects after a Single Intravenous or Oral Dose.
Drug Metab Dispos
; 49(8): 619-628, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34011533
6.
Switchability and minimal effect of food on pharmacokinetics of modified release tablet strengths of omecamtiv mecarbil, a cardiac myosin activator.
Biopharm Drug Dispos
; 42(7): 319-328, 2021 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-34087948
7.
Population pharmacokinetics of paritaprevir, ombitasvir, dasabuvir, ritonavir and ribavirin in hepatitis C virus genotype 1 infection: analysis of six phase III trials.
Br J Clin Pharmacol
; 83(3): 527-539, 2017 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-27662429
8.
Evaluation of Drug-Drug Interactions Between Hepatitis C Antiviral Agents Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir and HIV-1 Protease Inhibitors.
Clin Infect Dis
; 62(8): 972-9, 2016 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-26740513
9.
Evaluation of Drug-Drug Interactions between Direct-Acting Anti-Hepatitis C Virus Combination Regimens and the HIV-1 Antiretroviral Agents Raltegravir, Tenofovir, Emtricitabine, Efavirenz, and Rilpivirine.
Antimicrob Agents Chemother
; 60(5): 2965-71, 2016 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-26953200
10.
Drug-Drug Interactions between Sofosbuvir and Ombitasvir-Paritaprevir-Ritonavir with or without Dasabuvir.
Antimicrob Agents Chemother
; 60(2): 855-61, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26596948
11.
Drug Interactions with the Direct-Acting Antiviral Combination of Ombitasvir and Paritaprevir-Ritonavir.
Antimicrob Agents Chemother
; 60(1): 105-14, 2016 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-26459906
12.
Pharmacokinetics of Tacrolimus and Cyclosporine in Liver Transplant Recipients Receiving 3 Direct-Acting Antivirals as Treatment for Hepatitis C Infection.
Ther Drug Monit
; 38(5): 640-5, 2016 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-27310199
13.
Pharmacokinetics and safety of co-administered paritaprevir plus ritonavir, ombitasvir, and dasabuvir in hepatic impairment.
J Hepatol
; 63(4): 805-12, 2015 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-26070406
14.
Drug-drug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevir/ritonavir, ombitasvir, and dasabuvir.
J Hepatol
; 63(1): 20-9, 2015 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-25646891
15.
Population pharmacokinetics of levodopa in subjects with advanced Parkinson's disease: levodopa-carbidopa intestinal gel infusion vs. oral tablets.
Br J Clin Pharmacol
; 78(1): 94-105, 2014 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-24433449
16.
The H3 antagonist ABT-288 is tolerated at significantly higher exposures in subjects with schizophrenia than in healthy volunteers.
Br J Clin Pharmacol
; 77(6): 965-74, 2014 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-24215171
17.
Population pharmacokinetics of the 11ß-hydroxysteroid dehydrogenase type 1 inhibitor ABT-384 in healthy volunteers following single and multiple dose regimens.
Biopharm Drug Dispos
; 35(7): 417-29, 2014 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-25041811
18.
Effect of Strong CYP3A4 Inhibition, CYP3A4 Induction, and OATP1B1/3 Inhibition on the Pharmacokinetics of a Single Oral Dose of Sotorasib.
Clin Pharmacol Drug Dev
; 2024 Feb 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-38421129
19.
A multistate platform model for time-to-event endpoints in oncology clinical trials.
CPT Pharmacometrics Syst Pharmacol
; 13(1): 154-167, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-37860956
20.
Predicting Clinical Pharmacokinetics/Pharmacodynamics and Impact of Organ Impairment on siRNA-Based Therapeutics Using a Mechanistic Physiologically-Based Pharmacokinetic-Pharmacodynamic Model.
Clin Pharmacol Ther
; 115(5): 1054-1064, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38282246